A Phase I clinical trial (NCT03298763) of MSC-TRAIL for lung cancer is ongoing in the UK, which aims to establish the recommended MSC-TRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients 103. Here, TNFSF10 is linked to non-small cell lung carcinoma.